Non small cell lung cancer

Publishing Date : June, 2015
Report Code : HCOC102
Price:
Single license $4,500
Site license $6,300
Global license $7,200

“Non-Small Cell Lung Cancer Pipeline Analysis” report gives comprehensive insight on various drugs being developed for the treatment of Non-Small Cell Lung Cancer. The report discusses the unmet needs and strategies to overcome those. Also, covers some of the hot targets in research for treatment.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative opportunities in the non-small cell lung cancer market. The report also provides strategic insights on medicines that are likely to have an impact on non-small cell lung cancer treatment space and potentially alter standards of care in the foreseeable future. This helps in identifying the Best-in-class & First-in-class drugs.

Some of the key sections of report are given below:

Epidemiology

In this section, non-small cell lung cancer epidemiology is covered to understand the potential significance and impact of the disease.

  • Global prevalence & incidence rate based-on age groups and gender

Market analysis

In this section, global drugs market would be covered region-wise along with the CAGRs.

  • Forecasting model for market
  • Market dynamics
  • Global and regional drugs market

Pipeline Analysis

Pipeline analysis sections provides deeper insights on various drugs in discovery & development, pipelines from major companies would be covered along with potential targets, mechanism of action, current development status.

  • Pipeline analysis by developmental stage
  • Pipeline analysis by leading players
  • Pipeline analysis by targets & mechanism of action
  • IP status

Key Players Analysis

The key player’s analysis section provides an in-depth understanding of various companies working on non-small cell lung cancer in focus and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

  • Global key players overview
  • Global key players pipeline data
  • Global key players deal (collaborations, licensing, service agreements, grants, funds etc.)